These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29310464)

  • 1. Unwanted road to anaemia in transthyretin familial amyloid polyneuropathy may continue irrespective of tafamidis treatment.
    Ikeda T; Masuda T; Ueda M; Yamashita T; Misumi Y; Shinriki S; Ando Y
    Ann Clin Biochem; 2018 Sep; 55(5):571-575. PubMed ID: 29310464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
    J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
    Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
    J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tafamidis for transthyretin amyloidosis.
    de Lartigue J
    Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report].
    Miyazaki Y
    Nihon Ronen Igakkai Zasshi; 2017; 54(1):75-80. PubMed ID: 28202889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor excitability measurements in early stage familial amyloid polyneuropathy: The influence of tafamidis treatment.
    Casanova I; Caetano A; Díaz A; Conceição I; Brum M; de Carvalho M
    Neurophysiol Clin; 2020 Jul; 50(3):145-153. PubMed ID: 32507631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
    Lozeron P; Théaudin M; Mincheva Z; Ducot B; Lacroix C; Adams D;
    Eur J Neurol; 2013 Dec; 20(12):1539-45. PubMed ID: 23834402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S; Rossello A; Orlandini E
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
    Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tafamidis: a review of its use in familial amyloid polyneuropathy.
    Scott LJ
    Drugs; 2014 Aug; 74(12):1371-8. PubMed ID: 25022953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.
    Coelho T; Inês M; Conceição I; Soares M; de Carvalho M; Costa J
    Neurology; 2018 Nov; 91(21):e1999-e2009. PubMed ID: 30333157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
    Coelho T; Maia LF; da Silva AM; Cruz MW; Planté-Bordeneuve V; Suhr OB; Conceiçao I; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Grogan DR
    J Neurol; 2013 Nov; 260(11):2802-14. PubMed ID: 23974642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysical characterization and modulation of Transthyretin Ala97Ser.
    Liu YT; Yen YJ; Ricardo F; Chang Y; Wu PH; Huang SJ; Lin KP; Yu TY
    Ann Clin Transl Neurol; 2019 Oct; 6(10):1961-1970. PubMed ID: 31502419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
    Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
    Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
    Adams D; Cauquil C; Labeyrie C; Beaudonnet G; Algalarrondo V; Théaudin M
    Expert Opin Pharmacother; 2016; 17(6):791-802. PubMed ID: 26800456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Coelho T; Maia LF; Martins da Silva A; Waddington Cruz M; Planté-Bordeneuve V; Lozeron P; Suhr OB; Campistol JM; Conceição IM; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Wilson A; Grogan DR
    Neurology; 2012 Aug; 79(8):785-92. PubMed ID: 22843282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
    Tess DA; Maurer TS; Li Z; Bulawa C; Fleming J; Moody AT
    Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
    Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.